Excessive Drug Pricing: What It Is, And What It Isn't
It's difficult to know exactly how to define "excessive" or "unfair" pricing where pharmaceutical products are concerned, and many factors have to be taken into account. Even the EU Commission and competition authorities may be reluctant to pursue cases of alleged price gouging, lawyer David Hull told Informa's recent EU Pharma Law Forum in Brussels.
You may also be interested in...
As the Mylan EpiPen controversy in the US draws yet more attention to price increases on certain pharmaceutical products, an imminent decision by the UK competition authorities should help to clarify what should constitute “excessive” and “unfair” pricing.
When Valeant Pharmaceuticals International Inc. suddenly raised the prices of two critical drugs in the hospital setting, Nitropress (sodium nitroprusside) and Isuprel (isoprenaline), facilities had to find a way to deal with ensuring they had those vital medicines available, but doing so without breaking the bank.
The EU Orphan Regulation and the Paediatric Regulation have helped to increase the number of products developed for rare diseases and children, but they both have some shortcomings that need to be addressed, according to an evaluation of the legislation carried out by the EU authorities. The European pharmaceutical industry has warned against opening up the legislation, saying it is “critical to maintain a stable and predictable incentives framework."